$VERU News

Veru Completes Patient Enrollment In Phase 2b PLATEAU Clinical Trial To Evaluate Effect Of Oral Enobosarm 3 Mg Versus To Treat Obesity

Veru Announces $21.8M Sales ATM Program With Oppenheimer, Canaccord

Novo Nordisk Tests Wegovy Combinations In Older Adults With Veru Trial

This Small-Cap Biotech Just Soared Over 160% — What Is The Novo Nordisk Connection?

Veru Teams Up With Novo Nordisk for Obesity Combination Therapy Trial (VERU)

Canaccord Genuity Maintains Buy on Veru, Maintains $25 Price Target

Earnings call transcript: Veru Inc Q2 2026 shows improved financials

Oppenheimer Maintains Outperform on Veru, Lowers Price Target to $24

Veru Inc (VERU) Q2 2026 Earnings Call Highlights: Promising Clinical Trial Results Amid ...

Transcript: Veru Q2 2026 Earnings Conference Call

Veru Inc. (VERU) Q2 2026 Earnings Call Prepared Remarks Transcript

Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

Transcript: Veru Q2 2026 Earnings Conference Call

Veru Q2 EPS $(0.12) Beats $(0.28) Estimate

Veru to Report Fiscal 2026 Second Quarter Financial Results on May 13th

Veru Files Prospectus For Offering $200M Mixed Shelf

Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

Veru Enrolls First Patient In Phase 2b PLATEAU Clinical Trial Of Enobosarm, Oral SARM, To Preserve Muscle And Physical Function And To Augment Fat And Weight Loss When Combined With Wegovy

Veru Inc. (VERU) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference - Slideshow

Veru to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference